Regulatory
How Generic Medicines Make Treatment More Accessible
October 14, 2026
5 min read

More than seven in ten prescriptions subsidised through the Pharmaceutical Benefits Scheme (PBS) are for generic or biosimilar medicines. Yet they account for less than 30 per cent of what the Government spends on PBS medicines, according to the Generic and Biosimilar Medicines Association (GBMA).
A fundamental truth of our industry is that the benefits of a medicine can only be realised if it reaches the people who need it. A treatment that a patient cannot afford, or cannot find, has not yet fulfilled its true purpose.
The Early Bird Gets the Patent
Every innovative medicine begins in discovery, and discovery mostly ends in failure. While estimates vary, bringing a single medicine to market can cost anywhere from US$500 million to several billion dollars. This is the economics that innovative pharmaceutical companies live under: the few winners must earn back their own discovery costs and often the losses from projects that never reached a patient.
The system’s answer is the patent, a legally protected window in which only the inventor may sell the product. In Australia, the standard term is 20 years, and eligible pharmaceutical patents can be extended by up to five years to offset the time it takes to win regulatory approval.
The Same Medicine, at a Lower Cost
Generic pharmaceutical companies exist to make medicines accessible, in both senses of the word: affordable and available. The Therapeutic Goods Administration (TGA) describes a generic as an additional brand of an existing medicine. A generic medicine contains the same active ingredient as an original (“innovator” or “brand name”) medicine, in the same strength, form and route of administration. It reaches the market at a much lower cost, and the primary reason is that the supplier does not have to repeat the discovery process.
Once the patent on a protected medicine has expired, or been successfully challenged, other companies may legally manufacture and sell generics of that same medicine. While there is no need to repeat the discovery process, a generic supplier must show that its product is the “same”.
In Australia, a generic must be approved by the TGA and entered on the Australian Register of Therapeutic Goods (ARTG) before it can be sold. The TGA assesses the generic’s quality and safety, and the manufacturing site must meet Good Manufacturing Practice (GMP) standards. Another key requirement is bioequivalence: a company must demonstrate that its product delivers the active ingredient into the bloodstream at the same rate and to the same extent as the “innovator”. Generics bypass discovery, not regulation.
PBS
Most prescription medicines in Australia are subsidised through the PBS. From 1 January 2026, most people pay no more than $25.00 per PBS prescription, and the Government covers the remaining cost. Under PBS price disclosure, the Government periodically compares the prices at which companies actually sell their medicines with the PBS price, so that competition between brands flows through to what the scheme pays. This further drives down the cost for patients and frees up funding for new medicines.
Talk to Your Doctor or Pharmacist About Your Options
You should always speak with a healthcare professional before taking any medicine, whether it is an innovator product or a generic. A generic may be an option for anyone, but whether it is suitable for you depends on a range of factors, such as your condition, any allergies or sensitivities, and the other medicines you take.
This article is provided for general information and educational purposes only. It does not constitute medical advice and is not a substitute for advice from a qualified healthcare professional. Nova does not provide health advice and does not encourage or recommend the use of any medicine. Always talk to your doctor or pharmacist about your individual circumstances.
Share





